A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of TNBC or HER2+BC per ASCO/CAP guidelines . A tumor can be considered a TNBC if the ER or PR is \<10%. * Trial participants must have a diagnosis of LMD. They must have the presence of malignant cells in the CSF (CSF+; note now cytology is considered diagnostic of LMD if the cytology is read as positive or suspicious; OR characteristic radiographic abnormalities (see below) of LMD). Signs and symptoms of LMD in and of themselves are not sufficient for inclusion. * Patients must have an Eastern Cooperative Oncology Group performance scale of ≤ 3. * Coincident Brain or Spinal cord metastases are allowed if these are stable and do not require local therapy at the time of enrollment. Individuals with previously treated stable Brain metastases are eligible to participate. * Stereotactic Radiosurgery (SRS) and/or prior radiotherapy is permitted \> 2 weeks prior to initial Dendritic Cell (DC) vaccine dose. A follow up brain MRI should be obtained prior to DC vaccine to determine stability of the lesions. An interval of at least 4 weeks after the end of whole brain radiation or for any surgical resection of brain lesions is permitted. * Life expectancy of ≥ 8 weeks. * Demonstrate adequate organ function as defined in protocol. All screening labs should be performed with 14 days of treatment initiation. * Provision of signed and dated informed consent form. * Corticosteroids at doses equivalent to 8 mg dexamet…